title: Ovarian stimulation for in-vitro fertilization combining administration of gonadotrophins and blockade of the pituitary with D-Trp6-LHRH microcapsules: pilot studies with two protocols.
abstract: In women undergoing in-vitro fertilization and embryo transfer (IVF-ET), a total of 408 IVF cycles were stimulated using human menopausal gonadotrophin (HMG) or pure follicle stimulating hormone (FSH) plus HMG in combination with a single injection of D-Trp6-LHRH microcapsules in order to enhance the ovarian response to gonadotrophins and to avoid spontaneous LH surges. Sixty-seven pregnancies were achieved. Two protocols were employed. In protocol 1 ('blocking protocol', n = 268), the pituitary was first inhibited with a full dose (3.75 mg) of D-Trp6-LHRH in microcapsules and ovarian stimulation was started after the hypogonadotrophic hypogonadal state was ascertained (E2 less than 50 pg/ml). In protocol 2 ('flare-up protocol', n = 140), the treatment with D-Trp6-LHRH microcapsules (half-dose = 1.80 mg) and the ovarian stimulation with gonadotrophins were started at the same time. Higher doses of gonadotrophins were needed (39.5 +/- 11.2 ampoules FSH and/or HMG) in protocol 1, in which the pituitary was blocked prior to and during the stimulation, than in protocol 2 (20 +/- 9 ampoules) where the exogenous gonadotrophin stimulation appeared to be augmented by the initial agonistic effect of the injection of D-Trp6-LHRH microcapsules. In patients with purely tubal infertility, under 38 years old and no male factor, the results obtained with protocols 1 and 2 were similar in terms of pregnancy rate per cycle or per embryo transfer: 22.6 versus 20.5% and 28.3 versus 27.4%, respectively. However, considering the cost benefit, 'flare-up' protocols appeared to be a better choice and could be recommended.
authors.affiliation: Centre de Fécondation in Vitro Baudelocque, St-Vincent-de-Paul et Unité INSERM U 166, Paris, France.
authors.forename: J R
authors.initials: JR
authors.lastname: Zorn
authors.forename: M
authors.initials: M
authors.lastname: Barata
authors.forename: C
authors.initials: C
authors.lastname: Brami
authors.forename: S
authors.initials: S
authors.lastname: Epelboin
authors.forename: C
authors.initials: C
authors.lastname: Nathan
authors.forename: G
authors.initials: G
authors.lastname: Papageorgiou
authors.forename: P
authors.initials: P
authors.lastname: Quantin
authors.forename: F
authors.initials: F
authors.lastname: Rolet
authors.forename: M
authors.initials: M
authors.lastname: Savale
authors.forename: P
authors.initials: P
authors.lastname: Boyer
mesh_terms: D000328:Adult; D002214:Capsules; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D006062:Gonadotropins / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D010062:Ovulation Induction / Q000379:methods*; D010865:Pilot Projects; D010902:Pituitary Gland / Q000187:drug effects*; D017329:Triptorelin Pamoate
chemical_list: D002214:Capsules; D006062:Gonadotropins; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone